Journal of neurology, neurosurgery, and psychiatry
-
J. Neurol. Neurosurg. Psychiatr. · Oct 2014
Multicenter StudyIncreased mortality persists in an adult drug-resistant epilepsy prevalence cohort.
To investigate the cumulative probability of death and the standardised mortality ratio (SMR) in an adult drug-resistant epilepsy (DRE) population. ⋯ Mortality is increased in this drug-resistant population; largely driven by those with a known epilepsy aetiology. The increased mortality remains even after exclusion of those with a progressive aetiology. Previous studies of incident epilepsy cohorts revealed increased mortality that declines to near-normal levels after the first several years, but in our DRE cohort, mortality remains elevated despite a median duration of epilepsy of 25 years at study entry.
-
J. Neurol. Neurosurg. Psychiatr. · Oct 2014
Observational StudyAssessment of cancer risk with β-interferon treatment for multiple sclerosis.
The risk of cancer after exposure to the β-interferons (IFNβs) for multiple sclerosis (MS) has not been established. We assessed whether IFNβ treatment for MS is associated with cancer risk or the risk of specific cancers in a population-based observational study. ⋯ There was no evidence of an increased cancer risk with exposure to IFNβ over a 12-year observation period. However, the trend towards an association between IFNβ and breast cancer should be investigated further.
-
J. Neurol. Neurosurg. Psychiatr. · Oct 2014
Observational StudyAutologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.
Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. In this observational study, we describe the characteristics and outcome of the Swedish patients treated with HSCT for MS. ⋯ HSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres.